In-vivo subdermal implant in the alpha-Gal knockout mice model for the assessment of bioprosthetic heart valve calcification rate before and after a polyphenols-based treatment
暂无分享,去创建一个
C. Lotan | M. Padalino | A. Gandaglia | F. Naso | M. Spina | P. Zilla | A. Calafiore | A. Colli | G. Sturaro | Giulio Sturaro
[1] F. Nicotra,et al. Preventing extrinsic mechanisms of bioprosthetic degeneration using polyphenols. , 2022, European Journal of Cardio-Thoracic Surgery.
[2] R. Melder,et al. Polyphenols could be Effective in Exerting a Disinfectant-Like Action on Bioprosthetic Heart Valves, Counteracting Bacterial Adhesiveness , 2022, Cardiology and cardiovascular medicine.
[3] G. Gerosa,et al. The role of antibody responses against glycans in bioprosthetic heart valve calcification and deterioration , 2022, Nature Medicine.
[4] M. Wenk,et al. A reference map of sphingolipids in murine tissues. , 2021, Cell reports.
[5] J. Cornish,et al. Subcutaneous Surgical Rat Models for the Evaluation of Tissue-Engineered Heart Valve Immunogenicity: A Systematic Review , 2021, SSRN Electronic Journal.
[6] A. Kutikhin,et al. Degeneration of Bioprosthetic Heart Valves: Update 2020 , 2020, Journal of the American Heart Association.
[7] M. Dweck,et al. Pathophysiology of Aortic Stenosis and Future Perspectives for Medical Therapy. , 2020, Cardiology clinics.
[8] F. Schoen,et al. Preclinical Assessment of Cardiac Valve Substitutes: Current Status and Considerations for Engineered Tissue Heart Valves , 2019, Front. Cardiovasc. Med..
[9] Z. Tobota,et al. Trends in isolated aortic valve replacement in middle‐aged patients over the last 10 years: epidemiology, risk factors, valve pathology, valve types, and outcomes , 2019 .
[10] A. Gandaglia,et al. Alpha-Gal Inactivated Heart Valve Bioprostheses Exhibit an Anti-Calcification Propensity Similar to Knockout Tissues. , 2017, Tissue engineering. Part A.
[12] F. Platt,et al. Silencing the porcine iGb3s gene does not affect Galα3Gal levels or measures of anticipated pig‐to‐human and pig‐to‐primate acute rejection , 2016, Xenotransplantation.
[13] G. Heinze,et al. Suitability of the Rat Subdermal Model for Tissue Engineering of Heart Valves , 2014, Medical science monitor basic research.
[14] E. Lander,et al. Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.
[15] M. Antunes,et al. Low-dose acetyl salicylic acid versus oral anticoagulation after bioprosthetic aortic valve replacement. Final report of the ACTION registry. , 2013, International journal of cardiology.
[16] G. Gerosa,et al. First quantification of alpha‐Gal epitope in current glutaraldehyde‐fixed heart valve bioprostheses , 2013, Xenotransplantation.
[17] Yong Jin Kim,et al. Immune response to bovine pericardium implanted into α1,3-galactosyltransferase knockout mice: feasibility as an animal model for testing efficacy of anticalcification treatments of xenografts. , 2012, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[18] Alain Carpentier,et al. Cardiac xenotransplantation technology provides materials for improved bioprosthetic heart valves. , 2011, The Journal of thoracic and cardiovascular surgery.
[19] Alain Carpentier,et al. Gal knockout pig pericardium: new source of material for heart valve bioprostheses. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[20] K. Hoetzenecker,et al. Alpha-Gal Specific IgG Immune Response after Implantation of Bioprostheses , 2009, The Thoracic and cardiovascular surgeon.
[21] A. D'apice,et al. Anti‐Gal antibody‐mediated skin graft rejection requires a threshold level of Gal expression , 2008, Xenotransplantation.
[22] K. Feingold. The role of epidermal lipids in cutaneous permeability barrier homeostasis , 2007 .
[23] M. Sandrin,et al. The molecular basis for galalpha(1,3)gal expression in animals with a deletion of the alpha1,3galactosyltransferase gene. , 2006, Journal of immunology.
[24] E. Wolner,et al. Presence and elimination of the xenoantigen gal (alpha1, 3) gal in tissue-engineered heart valves. , 2005, Tissue engineering.
[25] W. Klepetko,et al. Alpha‐Gal on bioprostheses: xenograft immune response in cardiac surgery , 2005, European journal of clinical investigation.
[26] D. Sachs,et al. Marked prolongation of porcine renal xenograft survival in baboons through the use of α1,3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue , 2005, Nature Medicine.
[27] N. Mueller,et al. Heart transplantation in baboons using α1,3-galactosyltransferase gene-knockout pigs as donors: initial experience , 2005, Nature Medicine.
[28] E Wolner,et al. Early failure of the tissue engineered porcine heart valve SYNERGRAFT in pediatric patients. , 2003, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[29] P. Zilla,et al. Characterization of the immune response to valve bioprostheses and its role in primary tissue failure. , 2001, The Annals of thoracic surgery.
[30] P. Zilla,et al. Inflammatory and immune processes: the neglected villain of bioprosthetic degeneration? , 2001, Journal of long-term effects of medical implants.
[31] U. Galili,et al. Adult and neonatal anti‐Gal response in knock‐out mice for α1,3galactosyltransferase , 1998, Xenotransplantation.
[32] A. Robins,et al. The alpha-1,3-galactosyltransferase knockout mouse. Implications for xenotransplantation. , 1996, Transplantation.
[33] K. Gustafsson,et al. cDNA sequence and chromosome localization of pig alpha 1,3 galactosyltransferase. , 1995, Immunogenetics.
[34] U. Galili,et al. A Unique Natural Human Igg Antibody with Anti-a-galactosyl Specificity , 2022 .
[35] W. Norton,et al. Isolation and Characterization of Myelin , 1977 .
[36] B. Carabello,et al. Aortic stenosis , 2018, Rapid Cardiac Care.